Lv31
210 积分 2021-10-07 加入
Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
4小时前
待确认
The signaling pathways activated by ROR1 in cancer
3个月前
已完结
Nanobodies: from high-throughput identification to therapeutic development
3个月前
已完结
Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)
5个月前
已完结
Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs)
8个月前
已完结
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
9个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
9个月前
已完结
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
1年前
已完结
The pComb3 Phagemid Family of Phage Display Vectors
1年前
已完结
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
1年前
已完结
皖公网安备34019202002308
